Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
종목 코드 AQST
회사 이름Aquestive Therapeutics Inc
상장일Jul 25, 2018
CEOBarber (Daniel R)
직원 수142
유형Ordinary Share
회계 연도 종료Jul 25
주소30 Technology Dr
도시WARREN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호07059-5166
전화19089411900
웹사이트https://aquestive.com/
종목 코드 AQST
상장일Jul 25, 2018
CEOBarber (Daniel R)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음